Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer

Oncologist

Volumn 8, Issue 4, 2003, Pages 361-374

  Scagliotti, Giorgio V ^a   Turrisi III, Andrew T ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Chemotherapy; Docetaxel; Non small cell lung carcinoma; Radiotherapy; Review

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PLATINUM; RADIOSENSITIZING AGENT; VINBLASTINE;

AREA UNDER THE CURVE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG EFFICACY; DYSPHAGIA; ESOPHAGITIS; HUMAN; IRRADIATION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; LYMPHOCYTOPENIA; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PNEUMONECTOMY; PROGNOSIS; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; REMISSION INDUCTION; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0042709556     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-4-361     Document Type: Review

References (78)

1. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancer Base No. 5. Lyon, France: IARC Press, 2001.
2. Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, Fifth Edition. Philadelphia: Lippincott-Raven, 1997:858-911.
3. Blum A. Cancer prevention: preventing tobacco-related cancers. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, Fifth Edition. Philadelphia: Lippincott-Raven, 1997:545-557.
4. Ihde DC, Pass HI, Glatstein E. Small cell lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, Fifth Edition. Philadelphia: Lippincott-Raven, 1997:911-949.
5. Page NC, Read WL, Tierney RM et al. The epidemiology of small cell lung carcinoma. Proc Am Soc Clin Oncol 2002;21:305a.
6. Gandara DR, Lara PN Jr, Goldberg Z et al. Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non-small cell lung cancer: focus on docetaxel. Semin Oncol 2001;28(suppl 9):26-32.
7. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
8. National Cancer Institute. Cancer.gov. Non-small cell lung cancer (PDQ®): treatment. Health professional version. June 2002. Available at: http://www.cancer.gov/cancerinfo/pdg/treatment/non-small-cell-lung/ HealthProfessional#Section_101 (see page section: Stage IIIA Non-Small Cell Lung Cancer), accessed 11/07/02.
9. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158.
10. Rosell R, Gomez-Codina J, Camps C et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999;26:7-14.
11. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
12. Roth JA, Atkinson EN, Fossella F et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998;21:1-6.
13. Sugarbaker DJ, Herndon J, Kohman LJ et al. Results of cancer and leukemia group B protocol 8935. A mulfiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 1995;109:473-483; discussion 483-485.
14. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
15. Dillman RO, Herndon J, Seagren SL et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215.
16. Sause W, Kolesar P, Taylor S IV et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364.
17. Curran WJ Jr, Scott C, Langer C et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000;19:484a.
18. Furuse K, Kubota K, Kawahara M et al. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group. J Clin Oncol 1995;13:869-875.
19. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. The West Japan Lung Cancer Group. J Clin Oncol 1999;17:2692-2699.
20. Kawahara M, Kris MG, Green M et al. New drug and multi-modality combinations in the treatment of advanced non-small cell lung cancer. Semin Oncol 2001;28(suppl 9):1-4.
21. Cox JD, Azarnia N, Byhardt RW et al. N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991;20:7-12.
22. Gressen EL, Curran WJ. Hyperfractionated radiotherapy for lung cancer. Curr Oncol Rep 2000;2:71-75.
23. Senan S, Burgers S, Samson MJ et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys 2002;54:999-1006.
24. Mehta MP, Tannehill SP, Adak S et al. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593. J Clin Oncol 1998;16:3518-3523.
25. Saunders M, Dische S, Barrett A et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 1997;350:161-165.
26. Abratt RP, Bogart JA, Hunter A. Hypofractionated irradiation for non-small cell lung cancer. Lung Cancer 2002;36:225-233.
27. Slotman BJ, Njo KH, de Jonge A et al. Hypofractionated radiation therapy in unresectable stage III non-small cell lung cancer. Cancer 1993;72:1885-1893.
28. Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer 2002;38:223-230.
29. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 1996;56:1842-1850.
30. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999;9(suppl 1):12-26.
31. Mason KA, Hunter NR, Milas M et al. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997;3:2431-2438.
32. Mason KA, Kishi K, Hunter N et al. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res 1999;5:4191-4198.
33. Mason K, Staab A, Hunter N et al. Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 2001;18:599-606.
34. Amorino GP, Hamilton VM, Choy H. Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro. Radiat Oncol Investig 1999;7:343-352.
35. Michaud LB, Valero V, Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 2000;23:401428.
36. Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 1995;71:1194-1198.
37. Valero V, Jones SE, Von Hoff DD et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16:3362-3368.
38. Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000;27:145-157.
39. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
40. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
41. Rosell R. The integration of newer agents into neoadjuvant therapy. Semin Oncol 1998;25(suppl 8):24-27.
42. Gandara DR, Lara PN Jr, Goldberg Z et al. Neoadjuvant therapy for non-small cell lung cancer. Anticancer Drugs 2001;12(suppl 1):S5-S9.
43. Betticher DC, Hsu Schmitz SF, Gauthier Y et al. Neoadjuvant chemotherapy with docetaxel (Taxotere) and cisplatin in patients with non-small cell lung cancer, stage IIIA, N2 is highly active with few toxicities. Proc Am Soc Clin Oncol 1999;18:473a.
44. Griesinger F, Kern W, Binder L et al. Outpatient Taxotere/carboplatin combination therapy in NSCLC for induction in stage III B and palliation in stage IV. Proc Am Soc Clin Oncol 1998;17:487a.
45. Zarogoulidis K, Kontakiotis T, Hatziapostolou P et al. A phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer 2001;32:281-287.
46. Katakami N, Okazaki M, Nishimura T et al. Phase II trial of induction carboplatin and docetaxel with concurrent radiation in early-stage non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000;19:524a.
47. Belani C. Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: interim analysis. Semin Oncol 2001;28(suppl 9):10-14.
48. Fossella F. Docetaxel + cisplatin and docetaxel + carboplatin vs vinorelbine + cisplatin in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: results of a multicenter, randomized phase III study. Proc Eur Cancer Conf 2001;37(suppl 6):S 154.
49. Gralla RJ, Rodrigues J, Von Pawel J et al. Prospective analysis of quality of life in a randomized multinational phase III study comparing docetaxel plus either cisplatin or carboplatin with vinorelbine plus cisplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2002;21:300a.
50. Pisters KM, Ginsberg RJ, Giroux DJ et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000;119:429-439.
51. Schwarzenberger PO, Barron S, Wynn R et al. Docetaxel chemosensitization with once weekly, hypofractionated thoracic irradiation. Proc Am Soc Clin Oncol 2002;21:211b.
52. Komaki R, Seiferheld W, Ettinger D et al. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys 2002;53:548-557.
53. Curran W, Scott C, Langer C et al. Phase III comparison of sequential vs concurrent chemo-radiation for pts with unresected stage III non-small cell lung cancer: report of Radiation Therapy Oncology Group (RTOG) 9410. Lung Cancer 2000b;29(suppl 1):93a.
54. Komaki R, Seiferheld W, Curran W et al. Sequential vs concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer: analysis of failures in a phase III study (RTOG 9410). Int J Radiat Oncol Biol Phys 2000;48(suppl 3):113a.
55. Aamdal S, Hallén MN, Tonelli D et al. Docetaxel (Taxotere) combined with radiation in locally advanced non-small-cell lung cancer (NSCLC) - a phase I/II study. Proc Am Soc Clin Oncol 1998;17:476a.
56. Koukourakis MI, Kourousis C, Kamilaki M et al. Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer: a phase I/II dose escalation trial. Eur J Cancer 1998;34:838-844.
57. Choy H, DeVore RF, Hande KR et al. Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) trial. Lung Cancer 2001;34:441-449.
58. Mauer AM, Masters GA, Haraf DJ et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1998;16:159-164.
59. Choy H, DeVore RF, Hande KR et al. A phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt Cancer Affiliate Network (VCCAN) trial. Clin Lung Cancer 2000;1(suppl 1):S27-S31.
60. Aamdal S, Lauvvang G, Øwre K et al. A phase I/II study of docetaxel (Taxotere) combined with concurrent radiation therapy in locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2000;29(suppl 1):100.
61. Koukourakis MI, Bahlitzanakis N, Froudarakis M et al. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. Br J Cancer 1999;80:1792-1796.
62. Sistermanns J, Hoffmanns H. Phase II study of docetaxel with simultaneous radiochemotherapy in patients with locally advanced non-resectable non-small cell lung cancer (NSCLC) - preliminary results. Proc Am Soc Clin Oncol 1999;18:522a.
63. Hayman JA, Martel MK, Ten Haken RK et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001;19:127-136.
64. Williams TE, Thomas CR Jr, Turrisi AT 3rd. Counterpoint: better radiation treatment of non-small cell lung cancer using new techniques without elective nodal irradiation. Semin Radiat Oncol 2000;10:315-323.
65. Mudad R, Zakris EL. Concomitant docetaxel, cisplatin and radiation in the treatment of locally advanced non-small cell lung cancer: a phase I study. Proc Am Soc Clin Oncol 2000;19:544a.
66. Segawa Y, Ueoka H, Kiura K et al. A phase I/II study of docetaxel and cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 2000;19:508a.
67. Wu H-G, Bang Y-J, Choi EK et al. Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;52:75-80.
68. Yamamoto N, Nakagawa K, Uezima H et al. Phase I study of weekly chemotherapy of docetaxel + cisplatin with concurrent thoracic radiation therapy for unresectable stage III non-small cell lung cancer: correlation between A1-acid glycoprotein and esophagitis. Proc Am Soc Clin Oncol 2001;20:254b.
69. Nyman J, Mercke C. Docetaxel and cisplatin as induction and concomitant chemotherapy combined with accelerated radiotherapy for stage III non-small cell lung cancer - a phase II study. Proc Am Soc Clin Oncol 1999;18:518a.
70. Scagliotti GV, Manegold C, Buchholz E et al. Randomized phase II study evaluating the feasibility of thoracic radiotherapy with or without weekly docetaxel (Taxotere) following induction chemotherapy with cisplafin and docetaxel in unresectable stage IIIA/B non-small cell lung cancer. Proc Am Soc Clin Oncol 2002;21:320a.
71. Ramlau R, Scagliotti SV, Manegold C et al. Radiotherapy and concurrent weekly docetaxel following cisplatin-docetaxel induction chemotherapy in unresectable stage IIIA-B non-small-cell lung cancer: a randomised phase II trial. Ann Oncol 2002;13(suppl 5):134.
72. Vokes EE, Herndon JE 2nd, Crawford J et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 2002;20:4191-4198.
73. Murakami H, Kubota K, Ohe Y et al. Phase I study of weekly docetaxel and carboplatin with concurrent thoracic radiotherapy for stage III non-small cell lung cancer. Lung Cancer 2000;29(suppl 1):111.
74. Sakai H, Yoneda S, Noguchi Y et al. A phase I/II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with DOC/CBDCA for stage III unresectable non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:238b.
75. Skarin AT, Sugarbaker D, Berman S et al. Phase I study of carboplatin (CAR) and docetaxel (DOC) followed by weekly CAR/DOC with concurrent radiotherapy in stage III NSCLC. Proc Am Soc Clin Oncol 2001;20:277b.
76. Nishimura T, Ikeda A, Katakami N et al. Phase II study of induction carboplatin and docetaxel with concurrent thoracic radiation followed by surgical resection in stage IB, HA and IIB non-small cell lung cancer. Proc Am Soc Clin Oncol 2001;20:254b.
77. Gaspar L, Gandara D, Chansky K et al. Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIB non-small cell lung cancer (SWOG 9504): patterns of failure and updated survival. Proc Am Soc Clin Oncol 2001;20:315a.
78. Albain KS, Crowley JJ, Turrisi AT 3rd et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002;20:3454-3460.